Vinca is a pre-clinical stage biotech spun out from Macquarie University's oncology research arm. The technology uses custom siRNA sequences to silence genes that enable tumour cell migration and angiogenesis. The co-founder team includes published researchers and a former Roche medicinal chemist based in Sydney. They are raising a Series A to fund IND-enabling studies and manufacturing scale-up.